OncoMatch/Clinical Trials/NCT06207123
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Is NCT06207123 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for acute leukemia.
Treatment: Ponatinib · Vincristine · Dexamethasone · Methotrexate · LP-118 — The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
Creatinine clearance ≥50 mL/min, determined by the Cockroft-Gault formula, or measured by a 24-hour urine collection.
Liver function
AST and ALT ≤2.5 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e., leukemic involvement). For patients with Gilbert's syndrome, bilirubin ≤1.5 x of their baseline bilirubin level will be required.
Adequate organ function as defined by all of the following: Creatinine clearance ≥50 mL/min...AST and ALT ≤2.5 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e,, leukemic involvement). For patients with Gilbert's syndrome, bilirubin ≤1.5 x of their baseline bilirubin level will be required.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
- University of Rochester Medical Center, Wilmot Cancer Center · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify